Raghad O. Alharbi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Raghad O. Alharbi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Nasser Eid Alotaibi
College of Medicine, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia
2 shared publications - Shahad J. AlShammary
Department of Internal Medicine, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, 11671, Saudi Arabia
2 shared publications Bader A. Alotaibi
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
1 shared publicationBader Alotaibi
Department of Internal Medicine College of Medicine King Saud bin Abdulaziz University for Health Sciences Riyadh Saudi Arabia
1 shared publicationIhab F Suliman
Department of Internal Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
1 shared publicationIhab F. Suliman
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 1 February 2026
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 19, 1-12
Predictors of 90-Days Readmission and Emergency Visits Following Catheter Ablation for Arrhythmias: A Retrospective Study
Introduction: Although catheter ablation is a cornerstone in arrhythmia management, hospital readmissions, emergency room (ER) visits, and complications remain a significant clinical burden. Defining their frequency and predictors is essential to optimize patient follow-up and outcomes after ablation. Methods: To evaluate the rates and predictors of 90-day hospital readmissions and emergency room visits following catheter ablation, as well as procedure-related complications, among patients undergoing catheter ablation, a retrospective cohort study was conducted at King Abdulaziz Cardiac Center (Riyadh, Saudi Arabia), including adult patients undergoing catheter ablation between June 2022 and June 2024. Data were extracted from BestCare electronic medical records and analyzed using Fisher’s exact tests and logistic regression. Results: Among 176 patients, 13 (7.4%) were readmitted and 23 (13.1%) visited the ER, predominantly due to arrhythmia recurrence (61.5% and 60.9%, respectively). Recurrent events occurred in a subset of patients and were significantly more frequent among older individuals and those with a higher comorbidity burden (p< 0.01). Conclusion: Ninety-day readmissions and ER visits after catheter ablation were infrequent, mostly due to arrhythmia recurrence. Independent predictors included older age and comorbidity burden, underscoring the need for risk stratification and structured follow-up strategies to reduce preventable healthcare utilization.
- 1 February 2026
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 19, 1-12
Open AccessPredictors of 90-Days Readmission and Emergency Visits Following Catheter Ablation for Arrhythmias: A Retrospective Study
Introduction: Although catheter ablation is a cornerstone in arrhythmia management, hospital readmissions, emergency room (ER) visits, and complications remain a significant clinical burden. Defining their frequency and predictors is essential to optimize patient follow-up and outcomes after ablation. Methods: To evaluate the rates and predictors of 90-day hospital readmissions and emergency room visits following catheter ablation, as well as procedure-related complications, among patients undergoing catheter ablation, a retrospective cohort study was conducted at King Abdulaziz Cardiac Center (Riyadh, Saudi Arabia), including adult patients undergoing catheter ablation between June 2022 and June 2024. Data were extracted from BestCare electronic medical records and analyzed using Fisher’s exact tests and logistic regression. Results: Among 176 patients, 13 (7.4%) were readmitted and 23 (13.1%) visited the ER, predominantly due to arrhythmia recurrence (61.5% and 60.9%, respectively). Recurrent events occurred in a subset of patients and were significantly more frequent among older individuals and those with a higher comorbidity burden (p< 0.01). Conclusion: Ninety-day readmissions and ER visits after catheter ablation were infrequent, mostly due to arrhythmia recurrence. Independent predictors included older age and comorbidity burden, underscoring the need for risk stratification and structured follow-up strategies to reduce preventable healthcare utilization.
- Open Access
- 23 September 2025
- Published by Saudi Heart Association in Journal of the Saudi Heart Association
- Vol. 37 (4) , 1
Long-Term Survival in Lung Cancer with Brain Metastases and Coronary Artery Stenosis: A Case Report
Lung cancer is among the most diagnosed cancers worldwide, and its co-occurrence with coronary heart disease is life-threatening. Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung cancer (NSCLC). The addition of pemetrexed and carboplatin increases not only the efficacy but also the cardiotoxicity risk. We report a 59-year-old woman with NSCLC alongside brain, liver, and spleen metastases, who developed cardiovascular events following cancer therapy. With advanced imaging and multidisciplinary intervention, remarkable remission was achieved over two years. Reporting this case contributes to the understanding of its presentation and diagnostic challenges.
- 23 September 2025
- Published by Saudi Heart Association in Journal of the Saudi Heart Association
- Vol. 37 (4) , 1
Open AccessLong-Term Survival in Lung Cancer with Brain Metastases and Coronary Artery Stenosis: A Case Report
Lung cancer is among the most diagnosed cancers worldwide, and its co-occurrence with coronary heart disease is life-threatening. Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung cancer (NSCLC). The addition of pemetrexed and carboplatin increases not only the efficacy but also the cardiotoxicity risk. We report a 59-year-old woman with NSCLC alongside brain, liver, and spleen metastases, who developed cardiovascular events following cancer therapy. With advanced imaging and multidisciplinary intervention, remarkable remission was achieved over two years. Reporting this case contributes to the understanding of its presentation and diagnostic challenges.